Cancer Management ControversyPelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation TherapyPaly, Jonathan J. DO*; Deng, Mengying MMath†; Lee, Charles T. MD, PharmD*; Hayes, Shelly B. MD*; Galloway, Thomas J. MD*; Hallman, Mark A. MD, PhD*; Weiss, Stephanie E. MD*; Horwitz, Eric M. MD*; Price, Robert A. PhD*; Ma, C-M Charlie PhD*; Meyer, Joshua E. MD* Author Information Departments of *Radiation Oncology †Biostatistics, Fox Chase Cancer Center, Philadelphia, PA Supported in part through the NIH/NCI Cancer Center Support Grant P30 CA006927. The authors declare no conflicts of interest. Reprints: Joshua E. Meyer, MD, Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. E-mail: [email protected]. American Journal of Clinical Oncology: October 2020 - Volume 43 - Issue 10 - p 748-751 doi: 10.1097/COC.0000000000000741 Buy Metrics Abstract Pulsed low-dose rate radiation therapy has been shown to reduce normal tissue damage while decreasing DNA damage repair in tumor cells. In a cohort of patients treated with palliative or definitive pelvic reirradiation using pulsed low-dose rate radiation therapy, we observed substantial local control and low rates of toxicity. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.